Immunotech Biopharm Ltd Fundamental Analysis
Immunotech Biopharm Ltd (6978.HK) shows weak financial fundamentals with a PE ratio of -1.09, profit margin of 0.00%, and ROE of 2.93%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 446.8/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze 6978.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6978.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent6978.HK trades at attractive valuation levels.
Growth Score
Weak6978.HK faces weak or negative growth trends.
Financial Health Score
Moderate6978.HK shows balanced financial health with some risks.
Profitability Score
Weak6978.HK struggles to sustain strong margins.
Key Financial Metrics
Is 6978.HK Expensive or Cheap?
P/E Ratio
6978.HK trades at -1.09 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 6978.HK's PEG of 0.07 indicates potential undervaluation.
Price to Book
The market values Immunotech Biopharm Ltd at -19.78 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 1.28 times EBITDA. This is generally considered low.
How Well Does 6978.HK Make Money?
Net Profit Margin
For every $100 in sales, Immunotech Biopharm Ltd keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.93 in profit for every $100 of shareholder equity.
ROA
Immunotech Biopharm Ltd generates $-37.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.20 in free cash annually.
FCF Yield
6978.HK converts -51.69% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-1.09
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.07
vs 25 benchmark
P/B Ratio
Price to book value ratio
-19.78
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-31.60
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.35
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
2.93
vs 25 benchmark
ROA
Return on assets percentage
-0.38
vs 25 benchmark
ROCE
Return on capital employed
-1.54
vs 25 benchmark
How 6978.HK Stacks Against Its Sector Peers
| Metric | 6978.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -1.09 | 29.63 | Better (Cheaper) |
| ROE | 293.08% | 223.00% | Excellent |
| Net Margin | 0.00% | -38669.00% (disorted) | Weak |
| Debt/Equity | -31.60 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 0.35 | 4.30 | Weak Liquidity |
| ROA | -37.98% | -379.00% (disorted) | Weak |
6978.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Immunotech Biopharm Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation